Bridger Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bridger Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-18,778	Closed	-$7.35M	–	35
2025 Q3	$7.35M	Hold	18,778	–	–	3.96%	8
2025 Q2	$8.36M	Sell	18,778 -22,272	-54%	-$10.3M	4.93%	8
2025 Q1	$19.9M	Hold	41,050	–	–	9.89%	2
2024 Q4	$16.5M	Hold	41,050	–	–	8.88%	3
2024 Q3	$19.1M	Hold	41,050	–	–	9.55%	3
2024 Q2	$19.2M	Hold	41,050	–	–	9.9%	3
2024 Q1	$17.2M	Sell	41,050 -6,950	-14%	-$2.94M	7.74%	5
2023 Q4	$19.5M	Buy	48,000 +5,600	+13%	+$2.07M	7.49%	4
2023 Q3	$14.7M	Hold	42,400	–	–	5.4%	9
2023 Q2	$14.9M	Buy	+42,400	New	+$14.3M	4.95%	8
2023 Q1	–	Sell	-16,468	Closed	-$4.76M	–	31
2022 Q4	$4.76M	Sell	16,468 -23,304	-59%	-$7.1M	1.92%	18
2022 Q3	$11.5M	Sell	39,772 -33,300	-46%	-$9.58M	3.48%	10
2022 Q2	$20.6M	Sell	73,072 -9,728	-12%	-$2.6M	4.64%	8
2022 Q1	$21.6M	Buy	82,800 +23,400	+39%	+$5.55M	3.54%	13
2021 Q4	$13M	Buy	+59,400	New	+$11.6M	1.69%	22

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Bridger Management's VRTX Position: Q4 2025 in Review

Bridger Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 18,778 shares — an estimated $7.35M sold.

Bridger Management first reported a position in VRTX in Q4 2021 and held it in 15 quarters. The position peaked at $21.6M in Q1 2022. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Bridger Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Bridger Management sold 18,778 Vertex Pharmaceuticals shares in Q4 2025, an estimated $7.35M.
Bridger Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 15 quarters.
Bridger Management's Vertex Pharmaceuticals position peaked at $21.6M in Q1 2022.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Bridger Management's 13F filing for Q4 2025, filed 17 Feb 2026.